Pipeline Progress at Prothena
Moreover, Roche and Prothena will initiate a research collaboration focusing on optimizing early stage antibodies targeting alpha-synuclein. This research collaboration will include incorporation of Roche's proprietary Brain Shuttle(TM) technology to ...
Why Prothena Corporation PLC Shares Leaped HigherMotley Fool
First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's ...GlobeNewswire (press release)

all 12 news articles »